Author(s): Bever CT Jr, Salazar AM, Neely E, Ferraraccio BE, Rose JW,
Abstract Share this page
Abstract Eighteen patients with chronic progressive multiple sclerosis (MS) were treated in an open preliminary trial of the interferon inducer and immune modulator, poly ICLC. All patients produced substantial interferon levels and experienced acute side effects, including fever and transient worsening of neurologic symptoms. Of nine patients with rapid neurologic deterioration at the time of entry into the study, only three had disease progression during treatment. We conclude that poly ICLC can be administered safely to MS patients, and that a controlled trial will be necessary to determine efficacy.
This article was published in Neurology
and referenced in Journal of Clinical & Cellular Immunology